Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.8% – What’s Next?

Eli Lilly and Company (NYSE:LLY) shares shot up 1.8% during trading on Monday . The company traded as high as $1,008.93 and last traded at $1,008.4190. 2,797,338 shares were traded during mid-day trading, a decline of 15% from the average session volume of 3,284,525 shares. The stock had previously closed at $990.33.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly committed $500M to South Korea’s biotech sector, signaling accelerated R&D/partnering access and longer-term growth opportunities in APAC markets. Eli Lilly (LLY) Is Making a Big Bet on South Korea’s Biotech Sector. Here’s Why
• Positive Sentiment: Amazon Pharmacy expanded access to Lilly’s Zepbound KwikPen, improving patient convenience and potential uptake of its weight‑management franchise. Greater retail distribution tends to support sales growth. Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management
• Positive Sentiment: J.P. Morgan reaffirmed a buy rating on LLY, which supports investor confidence and can help buoy the stock amid mixed headlines. J.P. Morgan Keeps Their Buy Rating on Eli Lilly & Co (LLY)
• Neutral Sentiment: Coverage noting AI’s role in healthcare cites leaders like Lilly as potential long-term beneficiaries of AI-driven drug discovery/efficiency, but this is a thematic tailwind rather than an immediate catalyst. 2 Top AI Healthcare Stocks to Buy and Hold
• Neutral Sentiment: Industry distribution moves (Novo selling via Hims & Hers) reshape competitive dynamics in obesity drugs; this mainly affects Novo but increases market access complexity for all players. Novo Nordisk to Sell Ozempic, Wegovy Through Hims & Hers; Drops Lawsuit
• Negative Sentiment: A U.S. court certified a nationwide class of third‑party payors in racketeering litigation tied to Actos, renewing legal and potential cash‑flow liabilities for Lilly related to older diabetes drugs. This raises downside risk and headline volatility. Actos Class Action Puts Eli Lilly Legal And Cash Flow Risks In Focus
• Negative Sentiment: Lilly warned some basic Medicare plans may not follow the intended $50/mo out‑of‑pocket cap for weight‑loss drugs under the new model, creating pricing/reimbursement uncertainty that could affect patient access and uptake. Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs
• Negative Sentiment: Multiple commentary pieces flag Lilly’s rich valuation relative to peers and growth expectations, which can pressure the stock if top‑line growth slows or guidance disappoints. Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on LLY shares. Rothschild & Co Redburn upped their price target on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. Cantor Fitzgerald boosted their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank Of Canada assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 target price for the company. Finally, Leerink Partners boosted their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Trading Up 1.8%

The company has a 50 day moving average of $1,045.63 and a 200-day moving average of $942.56. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a market cap of $951.30 billion, a price-to-earnings ratio of 43.94, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period last year, the business posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LLY. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. State Street Corp grew its stake in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after purchasing an additional 635,358 shares in the last quarter. Capital Research Global Investors grew its stake in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Morgan Stanley increased its holdings in Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after purchasing an additional 407,166 shares during the period. Finally, Capital World Investors raised its position in Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.